Robert Karsunky

Direttore Finanziario/CFO presso Novartis Pharma AG

Health Technology

Consumer Services

Posizioni attive di Robert Karsunky

Società	Posizione	Inizio	Fine
Novartis Pharma AG Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.	Direttore Finanziario/CFO	01/07/2013	-
Cellestia Biotech AG Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.	Direttore/Membro del Consiglio	-	-

Società	Posizione	Inizio	Fine
ALCON INC.	Direttore Finanziario/CFO	03/11/2010	-

Universität zu Köln

Undergraduate Degree

Distribuzione geografica

Svizzera	4
Germania	2

Posizioni

Settori

Health Technology	4
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
ALCON INC.	Health Technology

Aziende private	2
Novartis Pharma AG Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.	Health Technology
Cellestia Biotech AG Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.	Health Technology

Aziende private

Health Technology